Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 34 | 2020 | 147 | 9.130 |
Why?
|
| Bronchodilator Agents | 13 | 2020 | 49 | 3.490 |
Why?
|
| Glycopyrrolate | 3 | 2019 | 3 | 1.810 |
Why?
|
| Muscarinic Antagonists | 3 | 2019 | 14 | 1.680 |
Why?
|
| Lung | 7 | 2019 | 265 | 1.580 |
Why?
|
| Patient Readmission | 3 | 2017 | 134 | 1.400 |
Why?
|
| Smoking | 13 | 2016 | 531 | 1.380 |
Why?
|
| Asbestos | 5 | 2015 | 8 | 1.340 |
Why?
|
| Forced Expiratory Volume | 11 | 2019 | 89 | 1.060 |
Why?
|
| Asthma | 6 | 2018 | 262 | 1.050 |
Why?
|
| Mesothelioma | 3 | 2015 | 39 | 0.980 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2018 | 11 | 0.970 |
Why?
|
| Disease Progression | 4 | 2017 | 594 | 0.950 |
Why?
|
| Administration, Inhalation | 10 | 2019 | 54 | 0.890 |
Why?
|
| Ethanolamines | 2 | 2015 | 9 | 0.840 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 121 | 0.730 |
Why?
|
| Humans | 44 | 2020 | 32798 | 0.680 |
Why?
|
| Spirometry | 4 | 2019 | 29 | 0.670 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2018 | 30 | 0.660 |
Why?
|
| Glucocorticoids | 2 | 2012 | 151 | 0.630 |
Why?
|
| Middle Aged | 26 | 2020 | 12125 | 0.620 |
Why?
|
| Respiratory System Agents | 1 | 2019 | 1 | 0.620 |
Why?
|
| Quinolones | 1 | 2019 | 7 | 0.620 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2015 | 9 | 0.600 |
Why?
|
| Indans | 1 | 2019 | 34 | 0.600 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 70 | 0.580 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 881 | 0.570 |
Why?
|
| Aged | 22 | 2020 | 10538 | 0.570 |
Why?
|
| Vital Capacity | 5 | 2019 | 42 | 0.550 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 428 | 0.540 |
Why?
|
| Male | 29 | 2020 | 19641 | 0.540 |
Why?
|
| Female | 28 | 2020 | 20261 | 0.540 |
Why?
|
| Medicare | 2 | 2017 | 213 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2010 | 1066 | 0.540 |
Why?
|
| Germ-Line Mutation | 2 | 2015 | 17 | 0.510 |
Why?
|
| Drug Combinations | 4 | 2019 | 99 | 0.490 |
Why?
|
| Treatment Outcome | 8 | 2019 | 3438 | 0.470 |
Why?
|
| Coronary Disease | 2 | 2016 | 214 | 0.470 |
Why?
|
| Benzyl Alcohols | 1 | 2015 | 1 | 0.460 |
Why?
|
| Chlorobenzenes | 1 | 2015 | 2 | 0.460 |
Why?
|
| Quinuclidines | 1 | 2015 | 3 | 0.460 |
Why?
|
| Androstadienes | 1 | 2014 | 17 | 0.440 |
Why?
|
| Albuterol | 1 | 2014 | 19 | 0.440 |
Why?
|
| Patient Selection | 1 | 2016 | 281 | 0.440 |
Why?
|
| Mutation, Missense | 2 | 2015 | 51 | 0.430 |
Why?
|
| Length of Stay | 1 | 2015 | 329 | 0.420 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 289 | 0.420 |
Why?
|
| Patient Discharge | 1 | 2015 | 204 | 0.420 |
Why?
|
| Algorithms | 1 | 2016 | 511 | 0.390 |
Why?
|
| Health Status | 5 | 2019 | 402 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 532 | 0.380 |
Why?
|
| Time Factors | 6 | 2020 | 2183 | 0.350 |
Why?
|
| Adult | 13 | 2019 | 9560 | 0.350 |
Why?
|
| Pleural Neoplasms | 2 | 2007 | 11 | 0.340 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 271 | 0.330 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2010 | 6 | 0.330 |
Why?
|
| Respiratory Function Tests | 4 | 2019 | 100 | 0.330 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 6 | 0.320 |
Why?
|
| Delayed-Action Preparations | 3 | 2016 | 36 | 0.320 |
Why?
|
| Age Factors | 5 | 2018 | 1197 | 0.310 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 208 | 0.300 |
Why?
|
| Inspiratory Capacity | 2 | 2020 | 2 | 0.300 |
Why?
|
| Dyspnea | 3 | 2019 | 33 | 0.290 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 4032 | 0.290 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 4 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 412 | 0.270 |
Why?
|
| Recovery of Function | 2 | 2019 | 203 | 0.270 |
Why?
|
| Peritoneal Neoplasms | 2 | 2007 | 263 | 0.270 |
Why?
|
| Interleukin-13 | 1 | 2007 | 28 | 0.270 |
Why?
|
| Comorbidity | 5 | 2016 | 573 | 0.260 |
Why?
|
| Environmental Exposure | 1 | 2007 | 89 | 0.260 |
Why?
|
| United States | 8 | 2020 | 4108 | 0.250 |
Why?
|
| Occupational Diseases | 1 | 2006 | 78 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 2 | 2003 | 63 | 0.240 |
Why?
|
| Risk Factors | 9 | 2019 | 3974 | 0.230 |
Why?
|
| Occupational Exposure | 2 | 2006 | 231 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 360 | 0.220 |
Why?
|
| Logistic Models | 6 | 2016 | 783 | 0.220 |
Why?
|
| Sex Factors | 5 | 2019 | 675 | 0.220 |
Why?
|
| Asbestosis | 1 | 2004 | 1 | 0.210 |
Why?
|
| Prostatic Neoplasms | 3 | 2003 | 476 | 0.200 |
Why?
|
| Prevalence | 7 | 2019 | 1002 | 0.200 |
Why?
|
| Inhalation | 2 | 2019 | 8 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 43 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 835 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 887 | 0.180 |
Why?
|
| Regression Analysis | 2 | 2017 | 288 | 0.180 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 183 | 0.180 |
Why?
|
| Hypercapnia | 1 | 2020 | 5 | 0.170 |
Why?
|
| Pulmonary Ventilation | 1 | 2020 | 14 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2015 | 1844 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 576 | 0.160 |
Why?
|
| Smoking Cessation | 3 | 2015 | 216 | 0.160 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 265 | 0.160 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2019 | 9 | 0.150 |
Why?
|
| Prognosis | 4 | 2015 | 1544 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 30 | 0.150 |
Why?
|
| Sleep | 1 | 2019 | 89 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 682 | 0.140 |
Why?
|
| North Carolina | 3 | 2019 | 1546 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3701 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2019 | 122 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 123 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2016 | 908 | 0.140 |
Why?
|
| Population Surveillance | 2 | 2016 | 128 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 128 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2018 | 147 | 0.130 |
Why?
|
| Health Education | 1 | 2018 | 162 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2010 | 876 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 259 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 105 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2017 | 68 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 240 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 490 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 143 | 0.120 |
Why?
|
| Stereoisomerism | 1 | 2015 | 20 | 0.110 |
Why?
|
| Genotype | 3 | 2007 | 731 | 0.110 |
Why?
|
| Melanoma | 1 | 2015 | 165 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 767 | 0.100 |
Why?
|
| Survival Rate | 1 | 2016 | 894 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2014 | 525 | 0.100 |
Why?
|
| Probability | 2 | 2004 | 157 | 0.100 |
Why?
|
| Adolescent | 4 | 2016 | 3638 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2015 | 1460 | 0.090 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2016 | 17 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 2327 | 0.080 |
Why?
|
| Macrophages | 2 | 2010 | 194 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2016 | 185 | 0.080 |
Why?
|
| Age Distribution | 2 | 2016 | 201 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 44 | 0.080 |
Why?
|
| Ethics, Professional | 1 | 2009 | 9 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 103 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2009 | 35 | 0.080 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 436 | 0.080 |
Why?
|
| ADAM Proteins | 1 | 2009 | 13 | 0.080 |
Why?
|
| Cell Survival | 1 | 2010 | 280 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2009 | 163 | 0.070 |
Why?
|
| Phenotype | 2 | 2009 | 638 | 0.070 |
Why?
|
| Neoplasms | 1 | 2015 | 761 | 0.070 |
Why?
|
| Laundering | 1 | 2007 | 4 | 0.070 |
Why?
|
| Clothing | 1 | 2007 | 6 | 0.070 |
Why?
|
| Nuclear Family | 1 | 2007 | 15 | 0.070 |
Why?
|
| Air Pollution, Indoor | 1 | 2007 | 10 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2010 | 820 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1152 | 0.070 |
Why?
|
| Linkage Disequilibrium | 2 | 2009 | 185 | 0.070 |
Why?
|
| Homozygote | 1 | 2007 | 58 | 0.070 |
Why?
|
| Heterozygote | 1 | 2007 | 61 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 20 | 0.060 |
Why?
|
| Family Health | 1 | 2006 | 78 | 0.060 |
Why?
|
| Health Surveys | 2 | 2018 | 200 | 0.060 |
Why?
|
| South Carolina | 2 | 2016 | 32 | 0.060 |
Why?
|
| Educational Status | 1 | 2006 | 183 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 199 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2003 | 459 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 2730 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 90 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2004 | 39 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2003 | 6 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 189 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 22 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 497 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 622 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2004 | 218 | 0.050 |
Why?
|
| Base Sequence | 1 | 2002 | 247 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 352 | 0.050 |
Why?
|
| Linear Models | 2 | 2015 | 445 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1572 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2002 | 246 | 0.040 |
Why?
|
| Child | 1 | 2007 | 2478 | 0.040 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 1 | 0.040 |
Why?
|
| Mutation | 1 | 2002 | 493 | 0.040 |
Why?
|
| Airway Resistance | 1 | 2019 | 4 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 947 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 57 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 410 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 2284 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 308 | 0.040 |
Why?
|
| Equipment Design | 1 | 2017 | 179 | 0.030 |
Why?
|
| Haplotypes | 2 | 2009 | 220 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 58 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 21 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 101 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 125 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 120 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 234 | 0.030 |
Why?
|
| Self-Help Devices | 1 | 2013 | 8 | 0.030 |
Why?
|
| Arthritis | 1 | 2013 | 42 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 488 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 217 | 0.020 |
Why?
|
| Genetic Markers | 2 | 2003 | 125 | 0.020 |
Why?
|
| Mental Health | 1 | 2013 | 128 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 258 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1238 | 0.020 |
Why?
|
| European Continental Ancestry Group | 2 | 2009 | 1163 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 679 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 422 | 0.020 |
Why?
|
| Constitution and Bylaws | 1 | 2009 | 3 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2009 | 24 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 220 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 609 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 976 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2003 | 10 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 20 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 31 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 73 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 135 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2002 | 7 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 40 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 71 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 96 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 140 | 0.010 |
Why?
|
| Quality of Life | 1 | 2008 | 961 | 0.010 |
Why?
|
| African Continental Ancestry Group | 1 | 2002 | 363 | 0.010 |
Why?
|